Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Van Malderen, Carine ^a,h   Van Geertruyden, Jean Pierre ^b   MacHevo, Sonia ^c   González, Raquel ^c,d   Bassat, Quique ^c,d   Talisuna, Ambrose ^e,f   Yeka, Adoke ^e   Nabasumba, Carolyn ^g   Piola, Patrice ^g   Daniel, Atwine ^g   Turyakira, Eleanor ^g   Forret, Pascale ^h   Van Overmeir, Chantal ^h   Van Loen, Harry ^h   Robert, Annie ^a   D Alessandro, Umberto ^h  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Ministério de Saúde   (Mozambique)

^d UNIVERSITY OF BARCELONA   (Spain)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g EPICENTRE   (France)

^h INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Artemisinin based combination therapy; Artesunate; Chlorproguanil dapsone; Conditional logistic regression; Glucose 6 phosphate dehydrogenase deficiency; Malaria; Mozambique; Restriction fragment length polymorphisms; Uganda

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; CHLORPROGUANIL PLUS DAPSONE; DIHYDROARTEMISININ PLUS PIPERAQUINE; HEMOGLOBIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CHLOROGUANIL, DAPSONE DRUG COMBINATION; DAPSONE; DRUG DERIVATIVE; PROGUANIL;

AFRICA; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HOMOZYGOSITY; HUMAN; MALARIA; MALE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME; AFRICA SOUTH OF THE SAHARA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HEMOLYTIC ANEMIA; INFANT; METHODOLOGY; MULTICENTER STUDY;

AFRICA SOUTH OF THE SAHARA; ANEMIA, HEMOLYTIC; ANTIMALARIALS; ARTEMISININS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; DAPSONE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; INFANT; MALARIA; MALE; PROGUANIL;

EID: 84862203792     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-139     Document Type: Article

References (31)

1. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, Pamba A, Duparc S, Goh LE, Harrell E, Carter N, Ward SA, Greenwood B, Winstanley PA, Am J Trop Med Hyg 2009 81 969 978 10.4269/ajtmh.2009.09-0351 19996424
2. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA, Lancet 2004 363 1843 1848 10.1016/S0140-6736(04)16350-2 15183620 (Pubitemid 38748637)
3. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W, Lancet 2001 358 1218 1223 10.1016/S0140-6736(01)06344-9 11675058 (Pubitemid 33010845)
4. Chlorproguanil-dapsone for malaria in Africa. Looareesuwan S, Imwong M, Wilairatana P, Lancet 2004 363 1838 1839 10.1016/S0140-6736(04)16390-3 15183616 (Pubitemid 38748634)
5. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemdé R, Greenwood B, Ward SA, Winstanley PA, PLoS One 2009 4 6682 10.1371/journal.pone.0006682 19690618
6. World Health Organization, Antimalarial chlorproguanil-dapsone (LapDapTM) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (DacartTM) versus artemether-lumefantrine (Coartem) and confirmation of findings in a comparative trial of LapDapTM versus DacartTM WHO, Switzerland 2008
7. Clinical and laboratory parameters in dapsone acute intoxication. Carrazza MZ, Carrazza FR, Oga S, Rev Saude Publica 2000 34 396 401 10.1590/S0034-89102000000400013 10973160
8. Glucose-6-phosphate dehydrogenase deficiency. Cappellini MD, Fiorelli G, Lancet 2008 371 64 74 10.1016/S0140-6736(08)60073-2 18177777
9. G6PD deficiency. Beutler E, Blood 1994 84 3613 3636 7949118 (Pubitemid 24362456)
10. The extent of linkage disequilibrium caused by selection on G6PD in humans. Saunders MA, Slatkin M, Garner C, Hammer MF, Nachman MW, Genetics 2005 171 1219 1229 10.1534/genetics.105.048140 16020776 (Pubitemid 43234853)
11. G6PD deficiency: the genotype-phenotype association. Mason PJ, Bautista JM, Gilsanz F, Blood Rev 2007 21 267 283 10.1016/j.blre.2007.05.002 17611006 (Pubitemid 47212602)
12. Glucose-6-phosphate dehydrogenase deficiency and malaria. Ruwende C, Hill A, J Mol Med 1998 76 581 588 10.1007/s001090050253 9694435 (Pubitemid 28332727)
13. G6PD deficiency assessment in Freetown, Sierra Leone, reveals further insight into the molecular heterogeneity of G6PD A-. Jalloh A, Jalloh M, Gamanga I, Baion D, Sahr F, Gbakima A, Willoughby VR, Matsuoka H, J Hum Genet 2008 53 675 679 10.1007/s10038-008-0294-y 18452027
14. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Beutler E, Duparc S, G6PD Deficiency Working Group, Am J Trop Med Hyg 2007 77 779 789 17978087 (Pubitemid 351844308)
15. ClinicalTrials.gov, http://www.clinicaltrials.gov
16. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. The Four Artemisinin-Based Combinations (4ABC) group, PLoS Med 2011 8 1001119 10.1371/journal.pmed.1001119 22087077
17. Severe and complicated malaria. World Health Organization, Trans R Soc Trop Med Hyg 1990 84 1 S65
18. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, Am J Trop Med Hyg 1995 52 565 568 7611566
19. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte TA, Bienzle U, Trop Med Int Health 2003 8 118 124 10.1046/j.1365-3156.2003.01008.x 12581435 (Pubitemid 36269361)
20. Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Kotea R, Kaeda JS, Yan SL, Sem Fa N, Beesoon S, Jankee S, Ramasawmy R, Vulliamy T, Bradnock RW, Bautista J, Luzzatto L, Krishnamoorthy R, Mason PJ, Br J Haematol 1999 104 849 854 10.1046/j.1365-2141.1999.01230.x 10192449 (Pubitemid 29143507)
21. A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone+artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Fanello CI, Karema C, Ngamije D, Uwimana A, Ndahindwa V, Van Overmeir C, Van Doren W, Curtis J, D'Alessandro U, Trans R Soc Trop Med Hyg 2008 102 412 420 10.1016/j.trstmh.2008.01.013 18328518
22. High risk of severe anaemia after chlorproguanil-dapsone + artesunate antimalarial treatment in patients with G6PD (A-) deficiency. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D, PLoS One 2008 3 4031 10.1371/journal.pone.0004031 19112496
23. The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R, Haematologica 2006 91 262 263 16461316
24. Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, Kirby PL, Woessner M, Neate C, Nyirenda M, Blencowe H, Dube-Mbeye Q, Kanyok T, Ward S, Molyneux M, Dunyo S, Winstanley PA, PLoS One 2008 3 1779 10.1371/journal.pone.0001779
25. Haematological study in Cabo Delgado province, Mozambique; sickle cell trait and G6PD deficiency. Nieuwenhuis F, Wolf B, Bomba A, De Graaf P, Trop Geogr Med 1986 38 183 187 3488609 (Pubitemid 16092461)
26. Host polymorphisms and the incidence of malaria in Ugandan children. Parikh S, Dorsey G, Rosenthal PJ, Am J Trop Med Hyg 2004 71 750 753 15642965 (Pubitemid 40075624)
27. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Beutler E, Mitchell M, Blood 1968 32 816 818 4386875
28. Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. Meissner PE, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, Müller O, Schirmer RH, Mockenhaupt FP, Bienzle U, Br J Haematol 2005 131 395 399 10.1111/j.1365-2141.2005.05778.x 16225660 (Pubitemid 43899672)
29. Formation and identification of a degradant in chlorproguanil-dapsone- artesunate (Dacart) tablets. Bardsley B, Barry SJ, Drozdz MA, Hancock SA, Okafo GN, Szafran MM, J Pharm Biomed Anal 2011 54 610 613 10.1016/j.jpba.2010.09.033 20970278
30. Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Ochong E, Bell DJ, Johnson DJ, D'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA, Owen A, Antimicrob Agents Chemother 2008 52 3883 3888 10.1128/AAC.00431-08 18725445
31. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Krudsood S, Imwong M, Wilairatana P, Pukrittayakamee S, Nonprasert A, Snounou G, White NJ, Looareesuwan S, Trans R Soc Trop Med Hyg 2005 99 142 149 10.1016/j.trstmh.2004.07.001 15607340 (Pubitemid 40028795)